Amphotericin B (generic), Fungizone Newswire

Amphotericin B (generic), Fungizone Newswire

Comprehensive Real-Time News Feed for Amphotericin B (generic), Fungizone.

Results 1 - 20 of 87 in Amphotericin B (generic), Fungizone

  1. Isolation and characterization of Candida spp. in Jordanian cancer...Read the original story

    Wednesday Dec 6 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. The presence of Candida spp.

    Comment?

  2. Epidemiology of oral yeast colonization and infection in patients...Read the original story

    Wednesday Dec 6 | CiteULike

    The aim of this study was to investigate the epidemiology of oral yeast colonization and infection amongst cancer patients. Patients with solid tumor, head-neck cancer or hematological malignancy were recruited into the study.

    Comment?

  3. Nam Dia long, a Vietnamese folk formula, induces apoptosis in MCF-7...Read the original story w/Photo

    Sunday Dec 3 | BioMed Central

    The holistic approach of traditional medicine renders the identification of its mechanisms of action difficult. Microarray technology provides an efficient way to analyze the complex genome-wide gene expression of cells treated with mixtures of medicinal ingredients.

    Comment?

  4. Basilea Snags Extended $226M+ Antifungal Deal With PfizerRead the original story w/Photo

    Thursday Nov 30 | BioSpace

    Isavuconazole is an antifungal for the treatment of life-threatening invasive mold infections. Ronald Scott, Chief Executive Officer of Basilea, said: "Cresemba is a well differentiated drug that addresses a critical medical need in patients with invasive mold infections.

    Comment?

  5. Basilea extends existing license agreement with Pfizer for antifungal ...Read the original story

    Thursday Nov 30 | Customer Interaction Solutions

    Basilea Pharmaceutica Ltd. announced today that Basilea Pharmaceutica International Ltd. has amended its existing license agreement for Europe, Russia, Turkey and Israel with Pfizer Inc. for Basilea's Cresemba to include China and sixteen countries in the Asia Pacific region. Isavuconazole is an antifungal for the treatment of life-threatening invasive mold infections.

    Comment?

  6. In vitro evaluation of antileishmanial activity and toxicity of...Read the original story

    Wednesday Nov 29 | CiteULike

    Potential toxicity, costs, and drug-resistant pathogens necessitate the development of new antileishmanial agents. Medicinal and aromatic plants constitute a major source of natural organic compounds.

    Comment?

  7. The global ophthalmic therapeutics/drugs market is expected to reach USD 35.7 billion by 2025Read the original story w/Photo

    Tuesday Nov 28 | PR Newswire

    For instance, the recent approval of Zerviate for the treatment of allergic conjunctivitis in 2017 and Humira and Xiidra in 2016 as ophthalmic solutions for the treatment of uveitis and dry eyes are expected to boost the market growth. Numerous ongoing public-private partnership agreements in the pharmaceutical industry for the development of novel therapeutics are expected to provide this market with lucrative growth opportunities.

    Comment?

  8. Research and Markets LogoRead the original story w/Photo

    Friday Nov 24 | PR Newswire

    For instance, the recent approval of Zerviate for the treatment of allergic conjunctivitis in 2017 and Humira and Xiidra in 2016 as ophthalmic solutions for the treatment of uveitis and dry eyes are expected to boost the market growth. Numerous ongoing public-private partnership agreements in the pharmaceutical industry for the development of novel therapeutics are expected to provide this market with lucrative growth opportunities.

    Comment?

  9. Global Ophthalmic Therapeutics/Drug Market Analysis 2014-2017 &...Read the original story

    Friday Nov 24 | Customer Interaction Solutions

    Global Ophthalmic Therapeutics/Drug Market Analysis 2014-2017 & Forecasts to 2025 By Class, Disease And Segment Forecasts - Research and Markets Global Ophthalmic Therapeutics/Drug Market Analysis 2014-2017 & Forecasts to 2025 By Class, Disease And Segment Forecasts - Research and Markets Increase in funding by public and private bodies for conducting research on ocular disorders with the presence of strong emerging pipeline drugs are some of the factors responsible for the growth of ophthalmic therapeutics market.

    Comment?

  10. Antifungal susceptibility testing of Candida species isolated from...Read the original story w/Photo

    Monday Nov 20 | BioMed Central

    Antifungal susceptibility testing is a subject of interest in the field of medical mycology. The aim of the present study were the distributions and antifungal susceptibility patterns of various Candida species isolated from colonized and infected immunocompromised patients admitted to ten university hospitals in Iran.

    Comment?

  11. Ophthalmic Therapeutics Market Size Worth $35.7 Billion by 2025: Grand View Research, Inc.Read the original story

    Nov 2, 2017 | PR Newswire

    For instance, the recent approval of Zerviate for the treatment of allergic conjunctivitis in 2017 and Humira and Xiidra in 2016 as ophthalmic solutions for the treatment of uveitis and dry eyes are expected to boost the market growth. Numerous ongoing public-private partnership agreements in the pharmaceutical industry for the development of novel therapeutics are expected to provide this market with lucrative growth opportunities.

    Comment?

  12. Basilea reports on commercial progress of antifungal Cresemba in EuropeRead the original story

    Nov 2, 2017 | Customer Interaction Solutions

    Basilea Pharmaceutica Ltd. announced today that its licensing partner Pfizer recently launched the antifungal drug Cresemba in Spain. Pfizer is now commercializing the product in the major EU markets and Austria.

    Comment?

  13. Global Canine Leishmaniasis Management MarketRead the original story w/Photo

    Oct 31, 2017 | PR-inside.com

    Canine leishmaniasis is a vector-borne disease caused by the Leishmania infantum and Leishmania chagasi. Canine leishmaniasis is transmitted through the infected Phlebotominae flies.

    Comment?

  14. Gilead HCV Woes Continue and Investors are SpookedRead the original story w/Photo

    Oct 26, 2017 | BioSpace

    Gilead Sciences announced today its results of operations for the third quarter ended September 30, 2017. The financial results that follow represent a year-over-year comparison of the third quarter 2017 to the third quarter 2016.

    Comment?

  15. Gilead: A Buy After EarningsRead the original story w/Photo

    Oct 27, 2017 | Seeking Alpha

    Legacy products such as the HIV drugs and Hepatitis B treatments picked up the slack for the lagging Hep C sales during the quarter. Kite Pharma's pipeline not only added Yescarta into the mix; it added two CAR-T therapies, and one T-cell receptor product.

    Comment?

  16. Pharmacokinetics characterization of liposomal amphotericin B:...Read the original story

    Oct 24, 2017 | CiteULike

    AmBisome, a liposomal formulation of amphotericin B , shows different pharmacokinetics from the conventional formulation, amphotericin B deoxycholate . To characterize the clearance process of L-AMB, the form in which it exists in rat plasma, pharmacokinetics in hepatic or renal failure rats, cellular distribution in rat liver, and placental and milk transfer in rat were investigated.

    Comment?

  17. Strong Cresemba (isavuconazole) sales in the United States trigger...Read the original story

    Oct 22, 2017 | Customer Interaction Solutions

    Basilea Pharmaceutica Ltd. announced today that the sales of the antifungal CresembaA in the United States exceeded the threshold triggering the first sales milestone payment from Astellas Pharma Inc. to Basilea in the amount of CHF 5 million. David Veitch, Chief Commercial Officer of Basilea, said: "We are very pleased with the continued commercial success of Cresemba in the U.S. reflecting the medical need for agents treating invasive aspergillosis and invasive mucormycosis in adults and the increasing importance of Cresemba in the treatment of adults suffering from these potentially life-threatening invasive fungal infections that predominantly affect immunocompromised patients, such as patients with cancer and after transplantation."

    Comment?

  18. Assessment of novel oral lipid-based formulations of amphotericin B using an in vitro lipolysis modelRead the original story

    Oct 22, 2017 | CiteULike

    The purpose of this study was to investigate the intraluminal processing of novel oral lipid-based formulations of amphotericin B using an in vitro lipolysis model. Amphotericin B was formulated in three lipid-based formulations consisting of different lipid components; iCo-009, iCo-010 and iCo-011.

    Comment?

  19. Reviewing Matinas BioPharma HoldingsRead the original story w/Photo

    Oct 21, 2017 | AmericanBankingNews.com

    Matinas BioPharma Holdings and Senestech are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations. This is a breakdown of current ratings and price targets for Matinas BioPharma Holdings and Senestech, as reported by MarketBeat.com.

    Comment?

  20. Correlates of acute renal failure in patients receiving parenteral amphotericin B.Read the original story

    Oct 8, 2017 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. While parenteral amphotericin B is an effective therapy for serious fungal infections, it frequently causes acute renal failure .

    Comment?